Navelbine (Vinorelbine Tartrate)

Vinorelbine Tartrate, the active ingredient in Navelbine, is a Vinca alkaloid presented as an unknown/unknown for oral use. It treats non‑small cell lung cancer and breast cancer in adult patients.

GNH USA supplies Navelbine as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Vinorelbine Tartrate is used in the treatment of solid tumours that respond to antimitotic chemotherapy.

- Non‑small cell lung cancer: improves disease control and survival when used in approved regimens. - Breast cancer: contributes to tumor reduction in metastatic or advanced disease as part of combination therapy. - Advanced solid tumours: employed in multi‑drug protocols to enhance overall response rates.

Vinorelbine Tartrate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting - Neutropenia (low white blood cell count) - Anemia - Constipation - Fatigue - Mild alopecia

Serious or Rare Side Effects: - Febrile neutropenia (infection with fever) - Severe pulmonary toxicity (interstitial pneumonitis) - Anaphylactic or severe allergic reactions - Marked liver enzyme elevation - Severe hypotension - Thromboembolic events

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for toxicity.

- Monitor blood counts: perform regular complete blood count to detect neutropenia. - Assess liver function: check hepatic enzymes before and during treatment. - Evaluate cardiac status: consider baseline ECG in patients with cardiac disease. - Avoid in active severe infection: defer therapy until infection is controlled. - Use with caution in renal impairment: adjust dosing if needed. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Vinorelbine Tartrate can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase vinorelbine exposure. - Concurrent myelosuppressive agents: heighten risk of severe bone‑marrow suppression. - Live vaccines: immunosuppression can reduce vaccine efficacy and increase infection risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic levels. - Anticoagulants (warfarin, DOACs): monitor coagulation parameters for bleeding. - Diuretics: watch for electrolyte disturbances and renal function changes.